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Abstract
Objective—We previously demonstrated that upregulation of intermediate-conductance Ca2+-
activated K+ channels (KCa3.1) is necessary for mitogen-induced phenotypic modulation in isolated
porcine coronary smooth muscle cells (SMCs). The objective of the present study was to determine
the role of KCa3.1 in the regulation of coronary SMC phenotypic modulation in vivo using a swine
model of postangioplasty restenosis.
Methods and Results—Balloon angioplasty was performed on coronary arteries of swine using
either noncoated or balloons coated with the specific KCa3.1 blocker TRAM-34. Expression of
KCa3.1, c-jun, c-fos, repressor element -1 silencing transcription factor (REST), smooth muscle
myosin heavy chain (SMMHC), and myocardin was measured using qRT-PCR in isolated medial
cells 2 hours and 2 days postangioplasty. KCa3.1, c-jun, and c-fos mRNA levels were increased 2
hours postangioplasty, whereas REST expression decreased. SMMHC expression was unchanged at
2 hours, but decreased 2 days postangioplasty. Use of TRAM-34 coated balloons prevented KCa3.1
upregulation and REST downregulation at 2 hours, SMMHC and myocardin downregulation at 2
days, and attenuated subsequent restenosis 14 and 28 days postangioplasty. Immunohistochemical
analysis demonstrated corresponding changes at the protein level.
Conclusion—Blockade of KCa3.1 by delivery of TRAM-34 via balloon catheter prevented smooth
muscle phenotypic modulation and limited subsequent restenosis.
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Coronary smooth muscle cells (SMCs) are phenotypically identified and characterized by
expression of smooth muscle specific marker genes, such as smooth muscle alpha actin
(SMαA), smooth muscle myosin heavy chain (SMMHC), and smoothelin-B. Unlike other cell
types, SMCs are not terminally differentiated and can alter their gene expression profile after
both physiological and pathophysiological stimuli, a phenomenon defined as phenotypic
modulation.1 During vasculoproliferative diseases, such as atherosclerosis and restenosis,
smooth muscle cells undergo phenotypic modulation characterized by suppression of smooth
muscle marker genes, increased proliferation, extracellular matrix synthesis, and migration.
2–5 We previously demonstrated that upregulation of intermediate-conductance Ca2+-
activated K+ channels (KCa3.1, IKCa1, encoded by the gene KCNN4), whose expression is
regulated by both AP-1 (c-jun/c-fos)6 and repressor element -1 silencing transcription factor
(REST),7 is necessary for mitogen-induced suppression of smooth muscle specific marker
genes, as well as SMC migration in porcine coronary SMCs in vitro.6 Relevance to coronary
disease was demonstrated by upregulation of KCa3.1 and decreased SMMHC in proliferating
coronary SMCs in an in vivo swine model of early atherosclerosis.6 The therapeutic potential
of KCa3.1 inhibitors was alluded to by the report that systemic delivery of TRAM-34 for 1 to
6 weeks decreased neointimal formation by ≈40% in the rat carotid injury model.8 Although
this demonstrated a critical role for KCa3.1 in neointimal hyperplasia, it did not address the
role of KCa3.1 in SMC phenotypic modulation per se. Additionally, the rat carotid injury model
differs in etiology from coronary postangioplasty restenosis in humans in both vessel type
(carotid versus coronary) and injury (lack of a medial tear).8–11 In contrast, the porcine
coronary overstretch injury model, widely recognized as the most appropriate model for
studying postangioplasty restenosis,11,12 produces a medial injury and development of a
smooth muscle-rich neointima nearly identical to what is seen in humans.9–12 The purpose of
the present study was to investigate the role of KCa3.1 in the regulation of coronary SMC
phenotypic modulation in a swine model of postangioplasty restenosis. Furthermore, we chose
to deliver TRAM-34,13,14 a specific KCa3.1 channel blocker,15 to the coronary vessel wall
via coated balloon catheter, to allow site-specific delivery and potentially avoid complications
of systemic TRAM-34 administration.
Materials and Methods
A detailed description of all methods is provided in the supplemental materials (available online
at http://atvb.ahajournals.org).
Coronary Balloon Angioplasty
Angioplasty was performed on the left circumflex (LCX) and left anterior descending (LAD)
coronary arteries of castrated male swine (27 to 47 kg; 6 to 8 months old). Animal protocols
were approved by the University of Missouri Animal Care and Use Committee in accordance
with the “Principles for the Utilization and Care of Vertebrate Animals Used in Testing,
Research, and Training.” Either the LCX or LAD was injured with a noncoated balloon,
whereas the remaining artery was injured with a TRAM-34 coated balloon (see supplemental
Figure I). After angioplasty, swine recovered for either 2 hours (n=5), 2 days (n=5), 14 days
(n=5), or 28 days (n=5). At the time of sacrifice, injured and noninjured segments of the LCX
and LAD were isolated and either quickly frozen in liquid nitrogen (LN2) for subsequent laser
capture microdissection and qRT-PCR or placed in paraformaldehyde for subsequent
immunohistochemistry.
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Balloon Coating
Balloons were inflated to 6 atm (nominal pressure), dipped in TRAM-34 (20 mg/mL in acetone)
for 10 seconds, and dried for 1 minute. This cycle was repeated 3 times and followed by a final
5-minute drying time. The balloon was then carefully deflated and immediately guided to the
coronary artery for balloon injury.
Laser Capture Microdissection and qRT-PCR
Laser capture microdissection of medial cells and qRT-PCR was performed as previously
described.6,16 Target gene expression was normalized to 18S using the 2−ΔΔCT method.17
Detection of TRAM-34 in the Vessel Wall
Using high-performance liquid chromatography (HPLC)-MS, TRAM-34 was quantified by its
base peak of 277 m/z (2-chlorotrityl fragment) and concentrations calculated with a 5-point
calibration curve. The related compound TRAM-46 (base peak of 261 m/z, 2-fluorotrityl
fragment) was used as an internal standard.
Statistics
All data are presented as mean±SE. One-way ANOVA was used for all group comparisons
with posthoc comparisons where appropriate. Significance was defined as P<0.05.
Results
KCa3.1 Is Necessary for Smooth Muscle Phenotypic Modulation Postangioplasty
qRT-PCR was used to measure mRNA in coronary medial cells isolated by laser capture
microdissection (Figure 1). Two hours postangioplasty (Figure 1 black bars), balloon injury
increased KCa3.1 mRNA by ≈23 fold (Figure 1a) and decreased REST, a transcription factor
which suppresses KCa3.1,7,18 by ≈5 fold (Figure 1b). TRAM-34 delivered via balloon catheter
(TRAM) blocked the increase in KCa3.1 mRNA (Figure 1a) and the decrease in REST mRNA
(Figure 1b) 2 hours postangioplasty. SMMHC mRNA was unchanged 2 hours after injury
(Figure 1c). Two days postangioplasty (Figure 1 gray bars), KCa3.1 mRNA remained elevated
(Figure 1a) while REST mRNA remained suppressed (Figure 1b), however the changes in
mRNA were not as robust as 2 hours postangioplasty. In contrast to 2 hours postangioplasty,
balloon injury suppressed SMMHC mRNA 2 days postangioplasty (Figure 1c). Importantly,
TRAM-34 delivered via balloon catheter blocked the increase in KCa3.1 mRNA (Figure 1a),
the suppression of REST (Figure 1b), and the loss of SMMHC (Figure 1c) mRNA two days
postangioplasty. These data demonstrate that after balloon injury, changes in coronary smooth
muscle KCa3.1 and REST precede alterations in SMMHC mRNA expression. Furthermore,
TRAM-34 prevented postangioplasty-induced changes in KCa3.1, REST, and SMMHC,
demonstrating that blockade of KCa3.1 can prevent phenotypic modulation in vivo.
Balloon injury also increased the AP-1 components, c-jun (Figure 1d) and c-fos (Figure 1e),
2 hours postangioplasty, consistent with previous findings in vitro demonstrating the role of
AP-1 in regulating KCa3.1 expression in smooth muscle cells and T cells.6,19 Interestingly,
TRAM-34 failed to prevent the upregulation of either c-jun or c-fos 2 hours postangioplasty
(Figure 1d and 1e). Lastly, we observed a transient increase in myocardin mRNA 2 hours
postangioplasty, before a decrease 2 days postangioplasty (Figure 1f), both of which were
blocked by TRAM-34. Myocardin has previously been demonstrated to regulate SMMHC
expression6,20–25 in vitro. Therefore, decreased myocardin as well as SMMHC mRNA 2 days
postangioplasty are consistent with previous data demonstrating the role of myocardin in
regulating SMMHC expression.20
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Delivery of TRAM-34 Into the Vessel Wall
To validate TRAM-34 transfer to the coronary wall, we measured TRAM-34 in arteries
harvested 2 hours, 2 days, and 14 days postangioplasty. TRAM-34 was detectable 2 hours (8.61
±3.97 ng/mg; n=2) as well as 2 days (0.52±0.28 ng/mg; n=2) postangioplasty in coronary
arterial segments injured with TRAM-34 coated balloons. By 14 days postangioplasty, only
0.7% of TRAM-34 detected 2 hours postangioplasty remained in the vessel wall (0.06 ng/mg;
n=1). TRAM-34 was not detectable in plasma at any point. However, low levels were detected
both 2 hours and 2 days postangioplasty in the liver (0.15 and 0.12 ng/mg, respectively), and
noninjured right coronary artery (0.45 and 0.12 ng/mg, respectively) demonstrating that low
levels of TRAM-34 were available systemically and accumulated in nontarget tissues,
consistent with the highly lipophilic nature of TRAM-34.
Immunohistochemistry 2 Hours and 2 Days Postangioplasty
Balloon angioplasty increased KCa3.1 protein expression (pink; Figure 2a black arrowheads),
and suppressed SMMHC protein expression (brown; Figure 2b white arrowheads) near the
medial tear (m=media). Therefore all comparative images in Figure 3 and 4 were taken at the
edge of the medial tear. Representative images demonstrate that compared to noninjured
(Control), balloon injury (Injured) increased KCa3.1 positive staining (Figure 3, top) both 2
hours and 2 days postangioplasty, an effect which was blocked by TRAM-34 coated balloons
(TRAM). Immunohistochemical analysis verified an ≈8-fold and an ≈12-fold increase in
KCa3.1 protein at 2 hours and 2 days postangioplasty, respectively; an effect completely
prevented by TRAM (Figure 5a). Consistent with SMMHC mRNA, representative images
stained for SMMHC protein demonstrated that balloon injury reduced SMMHC levels near
the medial tear 2 days after angioplasty, which was also prevented by the TRAM-34–coated
balloon (Figure 3, bottom), whereas SMMHC staining was unaltered 2 hours postangioplasty.
Immunohistochemical analysis demonstrated a 70% decrease in SMMHC protein 2 days
postangioplasty, which was completely prevented by TRAM (Figure 5b). Double labeling with
Ki-67 (blue, a marker of proliferating cells) and KCa3.1 (Figure 4 pink, top), indicated that
whereas all Ki-67–positive cells were also KCa3.1-positive, the converse was not true, ie, not
all KCa3.1-positive cells were proliferating.
Consistent with previous reports in vascular smooth muscle,7 we observed REST localized to
the nucleus of coronary smooth muscle (Figure 4). In uninjured control coronary arteries, REST
was ubiquitiously expressed in medial SMCs (100% REST-positive nuclei; Figure 4 and Figure
5c). Balloon injury significantly reduced the number of REST-positive cells by ≈50% 2 hours
and ≈40% 2 days postangioplasty, which was blocked by TRAM-34 coated balloons (Figure
4 and Figure 5c).
TRAM-34–Coated Balloons Reduced Restenosis
Coating balloons with TRAM-34 reduced the normalized intimal to medial thickness ratio
(IMT/RI) compared to noncoated balloons within the same animal. Representative histological
sections of segments injured with noncoated (Figure 6a) and TRAM-34–coated (Figure 6b)
balloons taken 28 days postangioplasty demonstrate that vessels injured with TRAM-34–
coated balloons had reduced neointima. Individual injury responses for TRAM-34 versus
uncoated balloons are given in supplemental Figure II. Summary data demonstrate that coating
balloons with TRAM-34 reduced postangioplasty restenosis by ≈38% and ≈22% at 14 and 28
days, respectively (Figure 6c), similar to what was previously published in the rat carotid injury
model.8 Acetone (vehicle)-coated balloons had similar IMT/RI (14.61±3.4) to the noncoated
balloons (15.59±2.7).
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Discussion
Recent studies have illustrated that the regulation of smooth muscle–specific marker gene
expression, and thus SMC phenotypic modulation, is largely dependent on ion channel
activity6,24; aka, excitation-transcription coupling.26,27 This study investigated the role of
KCa3.1 and its specific blocker TRAM-34 on excitation-transcription coupling in porcine
coronary SMC phenotypic modulation after balloon angioplasty. We also tested a new delivery
system for TRAM-34 via coated balloon catheters demonstrating that TRAM-34 was retained
in the vessel wall, effectively prevented injury induced decreases in SMMHC gene expression,
and reduced subsequent restenosis.
For these studies, we chose the porcine overstretch injury model because it is the closest
nonprimate model to human postangioplasty restenosis.11,12 Not only do swine have similar
coronary vessel anatomy (see supplemental Figure I) and medial thickness, but the neointima
that develops in response to injury is nearly identical to what is seen in humans.10–12,28–30
Furthermore, it allows use of standard balloons, catheters, and other equipment designed for
human coronary angioplasty. Therefore, the results obtained using the porcine model of
postangioplasty restenosis provide the best translational validation for human coronary artery
disease and restenosis treatments.
This study is the first to investigate the role of KCa3.1 and smooth muscle phenotypic
modulation during coronary postangioplasty restenosis. We demonstrated that balloon injury
robustly increased KCa3.1 and decreased REST expression 2 hours postangioplasty (Figure 1a
and 1b). Others have also demonstrated suppression of REST expression concurrent with
increased KCa3.1 expression.7 Interestingly, the present study demonstrated that TRAM-34
delivered via balloon catheter not only blocked injury-induced KCa3.1 upregulation, but also
the suppression of REST. It has previously been shown that delivery of the silencing
transcription factor, REST, to proliferating cells represses KCa3.1 expression,7 demonstrating
that REST regulates KCa3.1 expression.18 Our data suggests that expression of REST, in turn,
is regulated by KCa3.1 channel activity, as inhibition of KCa3.1 channel activity by TRAM-34
prevented the downregulation of REST postangioplasty. It is plausible that the initial
hyperpolarization or consequent potentiation of passive calcium entry attributable to KCa3.1
activity drives REST downregulation; however, this remains speculation, in part, because of
the lack of information on regulation of REST expression.31
Suppression of REST by KCa3.1 channel activity is, however, consistent with a positive, feed
forward mechanism for upregulation of KCa3.1 expression by KCa3.1 activity previously
observed in coronary smooth muscle cells in culture.6 We provide further support for this
model in the present study in vivo, where TRAM-34 also blocked upregulation of KCa3.1
mRNA postangioplasty.
A common downstream mechanism for increased KCa3.1 expression is likely via AP-1. In vitro
PDGF-BB induced upregulation of KCa3.1 mRNA, as well as binding of c-jun to the 5′ AP-1
binding site of the KCa3.1 promoter were blocked by TRAM-34.6 Both c-jun and c-fos are
components of the cis-binding element, AP-1,32 and the KCa3.1 promoter contains several
AP-1 binding sites.19,33 In the present study in vivo, both c-jun and c-fos were increased 2
hours postangioplasty, in association with the increase in KCa3.1 expression. However,
although TRAM-34 blocked injury-induced upregulation of KCa3.1 mRNA, it did not prevent
increases in c-fos or c-jun mRNA. The reason for this apparent dissociation of c-fos/c-jun from
KCa3.1 is not certain. However, our previous observations that TRAM-34 prevented PDGF-
BB–induced enrichment of the KCa3.1 promoter with c-jun and acetylated histone-4 (H4Ac)
indicate that TRAM-34 may prevent activation of the KCa3.1 promoter at the epigenetic level,
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ie, by preventing histone aceytlation and promoter availablity, rather than preventing increases
in c-fos/c-jun mRNA. Further investigation will be required to fully delineate this mechanism.
A primary goal of the present study was to determine whether KCa3.1 regulates coronary
smooth muscle phenotypic modulation in an in vivo model of postangioplasty restenosis. To
this end we clearly demonstrated that blockade of KCa3.1 could prevent postangioplasty
phenotypic modulation of coronary SMCs, as indicated by SMMHC gene expression. Balloon
injury decreased SMMHC gene expression 2 days postangioplasty, which was associated with
a simultaneous decrease in myocardin expression. This result was expected because of
previously published data demonstrating the role of myocardin in regulating SMMHC
transcription,20–26 and is consistent with reports in the mouse carotid injury model where
myocardin expression was not significantly decreased until 3 days after injury.34 Interestingly,
the decrease in myocardin mRNA seen at 2 days postangioplasty was preceded by a transient
increase 2 hours postangioplasty, a time when SMMHC mRNA is unchanged. This
“uncoupling” of myocardin from SMMHC expression has been reported previously and
proposed to result from the opposing interaction of myocardin with repressor trans-acting
factors. For example, Doi et al observed an elevation in HERP1 and myocardin in cultured
SMCs as well as in neointimal cells after rat aortic balloon injury, and overexpression of
HERP1 prevented myocardin-induced smooth muscle gene expression.35 Furthermore,
NOTCH signaling suppresses myocardin-induced smooth muscle gene expression36 by
targeting HERP1.35 Therefore, it is plausible that repressor trans-acting factors, eg, HERP1,
were also increased 2 hours postangioplasty, and prevented myocardin-induced SMMHC
expression.
We also examined protein levels associated with coronary balloon angioplasty to determine
whether they were consistent with changes in mRNA. Alterations in medial KCa3.1, REST,
and SMMHC protein as assessed by immunohistochemistry were consistent with mRNA levels
determined by qRT-PCR. Additionally, it is important to note that although many of the cells
near the medial tear of injured vessels stained positive for KCa3.1 (Figure 3, top), not all of
those cells were positive for Ki-67, a marker of proliferation. Thus, not all cells expressing
KCa3.1 are concurrently proliferating, although the majority of proliferating medial cells
express KCa3.1. These data are consistent with a model whereby coronary SMCs upregulate
KCa3.1 before entering the cell cycle, evidenced by inhibition of SMC proliferation by
TRAM-34.8
Although the focus of the present study was to determine the role of KCa3.1 in early gene
expression changes postangioplasty, we also determined whether acute, localized balloon
catheter delivery of TRAM-34 was effective at inhibiting subsequent neointimal lesion
formation. Local balloon catheter delivery of TRAM-34 inhibited neointimal formation by
38% at 14 days and 22% at 28 days postangioplasty, similar to the 40% reduction in intimal
thickening reported with daily systemic administration of TRAM-34 in a rat carotid injury
model.8 Thus, the present study provides translational validation by demonstrating similar
effects in the swine model of postangioplasty coronary restenosis, the industry standard for
preclinical coronary intervention. Although the development of drug eluting stents has
revolutionized interventional cardiology and effectively eliminated early restenosis, recent
evidence has demonstrated that patients with drug-eluting stents have higher rates of late
restenosis as well as late thrombosis,37 leading some38 cardiologists to advocate use of bare
metal stents or balloon angioplasty coupled with alternative drug delivery methods.37,39
Sheller et al demonstrated that paclitaxel delivered via coated balloon catheter significantly
reduced restenosis,39 prompting a call to pursue drug delivery by coated balloon catheter.37,
38 The present study is the first to report that catheter-based delivery of TRAM-34,14 a specific
KCa3.1 channel blocker,13,15 prevents phenotypic modulation of SMCs immediately after
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coronary angioplasty and limits subsequent restenosis, thus implicating KCa3.1 as a therapeutic
target in coronary vasculoproliferative disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TRAM-34 prevents angioplasty-induced phenotypic modulation
Relative mRNA of KCa3.1 (a), REST (b), SMMHC (c), c-jun (d), c-fos (e), and myocardin (f)
2 hours (black bars) and 2 days (gray bars) postangioplasty in non-injured (Control), balloon
injured (Injured), and TRAM-34–coated balloon injured (TRAM) coronary media. *P<0.05
vs corresponding control (n=4 to 5 per group).
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Figure 2. KCa3.1 and SMMHC protein 2 days postangioplasty
Representative coronary sections isolated 2 days postangioplasty stained for KCa3.1 (a, HRP,
pink) or SMMHC (b, DAB, brown). KCa3.1 staining was more intense (a, black arrowheads),
whereas SMMHC staining was more diffuse (b white arrowheads) near the medial tear.
Horizontal bar=100 µm.
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Figure 3. KCa3.1 and SMMHC histology 2 hours and 2 days postangioplasty
Representative cross-sections (8 µm; 4 to 5 per group) of control, injured, and TRAM-34–
coated balloon injured (TRAM) LCX and LAD 2 hours and 2 days postangioplasty exposed
to antibodies against KCa3.1 (1:600, pink, top), Ki-67 (1:200, blue, top), and SMMHC (1:800,
brown, bottom). Horizontal bar=100 µm.
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Figure 4. REST histology 2 hours and 2 days postangioplasty
Representative cross-sections (8 µm; 4 to 5 per group) of control, injured, and TRAM-34–
coated balloon injured (TRAM) LCX and LAD 2 hours and 2 days postangioplasty exposed
to anti-REST (1:50,000, brown), and counterstained with hematoxylin (blue nuclei were
considered REST negative). Horizontal bar=50 µm (25 µm in insets).
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Figure 5. Histological analysis of KCa3.1, SMMHC, and REST
KCa3.1 (a), SMMHC (b), and REST (c) staining were quantified using Image Pro Plus. Injury-
induced changes in KCa3.1, SMMHC, and REST staining were blocked by TRAM-34 (see
Figure 3 and Figure 4 for representative images). *P<0.05 vs respective control and †P<0.05
vs injured and control (n=4 to 5 per group).
Tharp et al. Page 14
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2009 March 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. TRAM-34 prevents restenosis 14 and 28 days postangioplasty
Representative coronary arteries injured with a noncoated (a) or TRAM-34 coated balloon (b)
28 days postangioplasty and stained with Verhoff van Giesen stain (VVG). TRAM-34 reduced
normalized intimal to medial thickness ratio (IMT/RI) at both 14 (38%) and 28 (22%) days
postangioplasty (c). *P<0.05 vs injured segment taken from the same animal (paired t test;
n=5). Horizontal bar=100 µm.
Tharp et al. Page 15
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2009 March 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
